Lexeo Therapeutics
LXEO
Lexeo Therapeutics (LXEO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.60
- EPS estimate
- −$0.68
- EPS surprise
- +11.69%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$0.68 | −$0.60 | +11.69% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.78 | −$0.99 | −26.39% | $0.00 | SEC |
| Q4 2024 | Mar 24, 2025 | −$0.81 | −$0.78 | +3.36% | $0.00 | SEC |
| Q3 2024 | Nov 13, 2024 | −$0.68 | −$0.89 | −31.19% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.69 | −$0.64 | +7.43% | $0.00 | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.70 | −$0.86 | −23.44% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Lexeo Therapeutics (LXEO) last report earnings?
Lexeo Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did LXEO beat earnings estimates?
Yes. Lexeo Therapeutics reported EPS of −$0.60 for Q2 2025 against a −$0.68 estimate — a 11.69% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.